Kornimate/medical-research-clean huggingface dataset:
clinical performance of two bulk-fill composite of posterior restorations

Conditions: Post Dental Restoration; Caries, Dental

Summary: to minimize the effects of polymerization shrinkage in the restorative treatment, there are new composites called bulk- fill which the companies has developed this composites for example tetric n ceram(ivoclar-vivadent) and filtek ( 3m espe). its decreased polymerization shrinkage and properties allow the material to be inserted in one layer being quickly than traditional composite. this clinical study is designed to compare the clinical performance of the bulk fill composite resin in class i (one-surface posterior), ii (two-surface posterior) and v (cervical-surface posterior) fillings.

a patients with 3 caries lesions class one either two or five will be divided into 3 groups , cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (bluephase style ivoclar-vivadent), with an energy 1,100 mw/cm² (±50 mw/cm²) and others group of cavities will be restored by bulk fill composite (3m espe) and other bulk fill composite ( ivoclar-vivadent) as one increment then will be cured as directed by the manufacturer with the light curing unit. the study will investigate the clinical performance and efficacy of a bulk-filled composite resin restorative material for a period of 5 years

Eligibility criteria:
inclusion criteria: * must have given written informed consent to participate in the trial * need at least three posterior restorations * must be available for the required post-operative follow-up visits * have a buccal to lingual/palatal width no greater than 1/3 the distance from buccal to lingual/palatal cusp tips * at least one occlusal and proximal contact on a natural tooth * cavities depth \> 2 mm in cervico-occlusal exclusion criteria: * have severe medical complications (organ transplants, long term antibiotic or steroid treatment, cancer or immunocompromised) and disabilities who may not be able to tolerate the time required to complete the restorations * have xerostomia either by taking medications known to produce xerostomia or those with radiation induced or sjogren's syndrome patients * chronic periodontitis * present with any systemic or local disorders that contra-indicate the dental procedures included in this study * an unstable occlusion * severe bruxing * teeth with periapical pathology or expected pulp exposures * are pregnant. * endodontically treated teeth
comparative study of empathy and anxiety in the different academic years, at the beginning of academic year and exam period in healthy students.

Conditions: Health Education; Health Promotion; Health Behavior

Summary: students from different health science degrees will carry out a study on the variables of empathy, anxiety and personality profile.

students from different health science degrees will carry out a study on the variables of empathy, anxiety and personality profile by means of validated questionnaires in order to compare them between different spanish regions and in different courses to be able to see their evolution and characteristics.

Eligibility criteria:
inclusion criteria: * men and women who are studying a health grade. * subjects that wish to participate in the study. exclusion criteria: * students who do not wish to participate in the study.

Keywords: health students anxiety empahty assessment personality health behavior
safety and immunogenicity of 3 lots of cell-derived subunit influenza vaccine as compared to 1 lot to egg-derived subunit influenza vaccine in healthy adults (>=18 to <=60)

Conditions: Influenza

Summary: the present study aims to evaluate safety, tolerability and immunogenicity of three lots of chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine licensed in europe.


Eligibility criteria:
inclusion criteria: 1. 18 to \<61 years of age 2. mentally competent to understand the nature, the scope and the consequences of the study 3. able and willing to give written informed consent prior to study entry 4. in good health as determined by: 1. medical history, 2. physical examination, 3. clinical judgment of the investigator. exclusion criteria: 1. unwilling or unable to give written informed consent to participate in the study 2. participation in another clinical trial of an investigational agent within 90 days prior to visit 1 and throughout the entire study 3. currently experiencing an acute infectious disease 4. any serious disease, such as, for example: 1. cancer, 2. autoimmune disease (including rheumatoid arthritis), 3. advanced arteriosclerotic disease or complicated diabetes mellitus, 4. chronic obstructive pulmonary disease (copd) requiring oxygen therapy, 5. acute or progressive hepatic disease, 6. acute or progressive renal disease, 7. congestive heart failure 5. surgery planned during the study period 6. bleeding diathesis 7. history of hypersensitivity to any component of the study medication or chemically related substances 8. history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine component 9. known or suspected impairment/alteration of immune function, for example resulting from: 1. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy), 2. receipt of immunostimulants, 3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within 3 months prior to visit 1 or planned during the full length of the study, 4. high risk for developing an immunocompromising disease 10. history of drug or alcohol abuse 11. laboratory-confirmed influenza disease within 6 months prior to visit 1 12. receipt of influenza vaccine within 6 months prior to visit 1 13. receipt of another vaccine within 60 days prior to visit 1, or planned vaccination within 3 weeks following study vaccination 14. any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or experienced fever (i.e., axillary temperature ≥ 38 degree c) within 5 days prior to visit 1 15. if female, pregnant or breastfeeding 16. if female, refusal to use a reliable contraceptive method during the three weeks following vaccination 17. planned relocation abroad during the study period 18. any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

Keywords: influenza flu cell-derived egg-derived healthy adults safety immunogenicity vaccination
fetus weight estimation by ultrasound data collection

Conditions: Fetal Weight

Summary: this research aims to allow deployment \& optimization of sampl plain wave algorithm so as to make required advancement towards a light-weight portable us platform or wireless probe - thus elevating clinician's care level and patient treatment by allowing more scan availability and flexibility.


Eligibility criteria:
inclusion criteria: 1. women between 24+0 weeks and 41+6 weeks gestation. 2. women with a singleton viable pregnancy. exclusion criteria: none
development of an algorithm for prediction of onset of hemodynamic instability in humans

Conditions: Hemorrhagic Shock

Summary: the purpose for this study is to measure the physiology of human undergoing a lower body negative pressure usea non-invasive low-power optical technique, near-infrared diffuse optical spectroscopy measurement and compare these measurement to standard monitoring procedures delineated in the brooke army medical center. the brooke army medical center can use near-infrared diffuse optical spectroscopy to provide functional physiologic tissue and organ information without ionizing radiation and without withdrawing any blood, in a cost-effective and rapid manner. monitoring for the onset of circulatory shock in a wounded soldier on the battlefield is typically performed by measurement of arterial blood pressure, arterial oxygen saturation, or simple auscultation of the pulse. shock is typically recognized by non-specific signs and subjective symptoms such as cold clammy skin, pallor, weak thready pulse, unstable vital signs, and diminished mentation.

the near-infrared diffuse optical spectroscopy can measure tissue regions deeper below the skin surface and reports on larger tissue volumes in muscle and brain. the near-infrared diffuse optical spectroscopy instrument generate harmless amounts of low-level non-ionizing near-infrared ligh can measure the tissue absorption and scattering properties at depths of 1 cm or more below the skin surface include larger tissue volumes in muscle and brain. the absorption properties of tissue provide and can determine absolute concentrations of deoxygenated hemoglobin, oxygenated hemoglobin, and water, as well as the total hemoglobin saturation.

Eligibility criteria:
inclusion criteria: * healthy nonsmoking normotensive males or females. * age 18 to 55 years old, military or civilian. * active duty military members who are 17 years old exclusion criteria: * age \ 55 years, except for 17 year old active duty military members. * history of hyperthyroidism,hypertension, cardiovascular abnormality, respiratory illnesses,anaphylaxis,pre-syncopal/syncopal episodes,abnormal blood clotting, * taking drugs to alter autonomic function * history of alcohol or drug abuse

Keywords: trauma situations lower body negative pressure (lbnp)
testing the application of mepitel film during radiation therapy to reduce radiation related redness and peeling in breast cancer patients following mastectomy

Conditions: Breast Carcinoma; Mastectomy Patient

Summary: this phase iii trial studies how well mepitel film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy. mepitel film may reduce the severity of skin redness and peeling in the area of radiation.

the primary and secondary objectives of the study: primary objectives: i. to determine the ability of mepitel film to reduce the severity of radiation dermatitis in patients undergoing post-mastectomy radiotherapy for breast cancer when compared to the institutional standard of care. key secondary objectives: i. to determine the ability of mepitel film to prevent radiation-induced dermatitis based on a centralized, blinded provider assessment review of photographs. ii. to determine the ability of mepitel film to prevent radiation-induced dermatitis based on a non-blinded institutional provider assessment. iii. to determine the ability of mepitel film to prevent radiation-induced dermatitis based on a combined patient and non-blinded institutional provider assessment. outline: patients are randomized to 1 of 2 arms. arm i: patients receive standard of care skin management during radiation therapy for up to 6 weeks. arm ii: patients receive mepitel film applied to breast or chest wall every week before radiation therapy for up to 6 weeks. after completion of study, patients are followed up at 7-14 days, 3 months, 6 months, 1 year, and 2 years.

Eligibility criteria:
inclusion criteria: * histologic confirmation of breast malignancy with tnm staging. * patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy. * no prior radiotherapy to any portion of the planned treatment site. * no documented history of adhesive or tape allergy. * patients must be scheduled to receive conventionally fractionated photon-based radiation. patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible. * no active rash or pre-existing dermatitis within the treatment field. * no co-existing medical conditions resulting in life expectancy \< 2 years. * no active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis). * no concomitant cytotoxic chemotherapy. endocrine therapy and her2 directed therapies are allowed. * no current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy. * no previous history of organ or bone marrow transplant. * eastern cooperative oncology group (ecog) performance status 0-1. * in order to complete the mandatory patient-completed measures, participants must be able to speak and read english.
osteopontin in metastatic breast cancer patients

Conditions: Survival, Prosthesis

Summary: opn plays an important role in various aspects of malignancy, particularly those involved in tissue invasion and metastasis, and opn levels have been associated with aggressive¬ness in several cancer types, including breast cancer. tumor response to treatment is a predictor of prognosis and overall survival for cancer patient population the investigators assigned osteopontin as potential contributors in breast cancer.

analysis of polymorphisms in the opn regulatory region: the pcr amplification of the promoter regulatory region from the extracted dna by using the following primers -3 (forward primer 5" -caa gct act gca tac tcg aaa tca ca-3" ; reverse primer 5" - aca acc aag ccc tcc cag aat tta-3" ). pcr was performed using 50 ng dna as a template under the following conditions: 95°c for 10 min, then 36 cycles of 94°c for 30 s, an annealing temperature for 60 s, and 72°c for 60 s, with a final extension at 72°c for 15 min. after affinity membrane purification using the qiaquick gel extraction kit (qiagen, carlsbad, ca, usa), the pcr products were subjected to cycle sequencing with the respective forward and reverse primer using an automated abi 310 dna sequencer. measurement of serum level of osteopontin: opn level were measured using enzyme linked immnosorbent (elisa) kit supplied by ibl (immuno-biological laboratories co. ltd., japan). 30 normal females were conducted with matched age with a median osteopontine serum level of 15 so, this level was assigned as a cut off value. pretreatment serum level and polymorphism of oteopontine was correlated with different clinicopathological criteria of the patients, response to the treatment, pfs and os.

Eligibility criteria:
inclusion criteria: * de novo metastatic breast cancer patients recruited from oncology center mansoura university and clinical oncology department, mansoura university hospital all included patients were presented with disseminated visceral +/- bone metastasis (visceral crisis) exclusion criteria: * brain metastasis was excluded
strength training and quality of life in elderly

Conditions: Quality of Life

Summary: aim: to evaluate the impact of three different strength training programs on psychological wellbeing of elderly.

background: physical activity in the elderly has benefits which improve psychological wellbeing. however, the majority of older adults perform less physical activity with advancing age. aim: to evaluate the impact of three different 32-week strength training programs (low, moderate and high intensity) on psychological wellbeing of elderly. design: randomized controlled trial.

Eligibility criteria:
inclusion criteria: * age ≥60 years; * having the ability to speak and write in spanish; * having the ability to complete the questionnaires independently. exclusion criteria: -the presence of any medical problem or pathology that could hinder physical activity practice
model 4196 left ventricular (lv) lead chronic performance study

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate long-term performance of the 4196 lv lead. this evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. the leads will be followed for 5 years after implant. this study is required by fda as a condition of approval of the model 4196 lv lead and is integrated within the product surveillance registry (pan registry).

model 4196 lv lead complication-free survivability will be summarized.

Eligibility criteria:
patients who meet all of the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment. inclusion criteria * patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements * patient has or is intended to receive an attain ability model 4196 lv lead * patient within 30 day post implant enrollment window exclusion criteria * patient who is, or is expected to be inaccessible for follow-up * patient with exclusion criteria required by local law * patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
impact of cannabis consumption on the course, modalities of hospitalization and the short-term prognosis of inpatients suffering from psychotic symptoms

Conditions: Psychotic; Disorder, Cannabis

Summary: few studies have evaluated, in patients with symptomatology the impact of cannabis use on the duration of hospitalization and on short- and medium-term developments. the objective of this study will be to assess the impact of cannabis on the duration, the hospitalization and the short- and medium-term evolution of patients with psychotic symptoms and cannabis use. we hypothesize that these patients (in comparison with patients with psychotic symptomatology and not using cannabis) would be hospitalized more long, exposed to a higher risk of resistance to the usual therapeutics, would have a lack of therapeutic alliance and insight, relapses and hospitalizations more frequent, more marked negative symptoms and lower quality remission. they would also be more prone to impulsive and aggressive behaviour.

several studies have reported that cannabis use worsen the prognosis of psychiatric pathologies in general and psychotic in particular. few or no studies have evaluated the impact of cannabis consumption on patients with psychotic symptoms during their hospitalization (duration, type of hospitalization, quality of relationship with staff hospital), and on the short-term prognosis. the objective of this study will be to assess the impact of cannabis on the duration of the hospitalization and the short- and medium-term evolution of patients with a psychotic symptomatology and cannabis use. making the hypothesis that these patients (compared to patients with symptomatology psychotic and not using cannabis) would be hospitalized longer, exposed at a higher risk of resistance to the usual therapies, to have a lack of alliance therapeutic and insight, relapses and more frequent hospitalizations and symptoms. they would also be more likely to have lower quality. they would also be more likely to be impulsive, and have aggressive behaviours.

Eligibility criteria:
inclusion criteria: * hospitalized in psychiatry regardless of the mode of hospitalization * with or without protective measures (guardianship or curatorship) * presenting psychotic symptoms (schizophrenia, schizo affective disorder, thymic disorder with psychotic characteristic, psychotic disorder substance-induced, brief psychotic disorder, schizophrenic disorders, delirious disorders) * members of the social security system * enlightened information exclusion criteria: * degenerative neurological pathologies or mental retardation * psychotic disorders secondary to generalized medical conditions(epilepsy, delirium tremens, tumors, etc.) * other psychiatric pathologies

Keywords: cannabis-timing-hospitalization-psychotic sympyomatology
prospective study for transplant optimization using functional imaging (trofi)

Conditions: Bronchiolitis Obliterans; Lung Transplant Rejection

Summary: the objective of this study is to detect bos in an early stage by using the outcome parameters generated by functional respiratory imaging (fri). robust and automated segmentation algorithms will be developed for these parameters, focusing on quantitative computed tomography (ct) image analyses to provide the physician a more sensitive diagnostics tool. the evolution of rejection over time will be monitored using non-rigid image registration methods.


Eligibility criteria:
inclusion criteria: * male or female patient ≥ 18 years old * written informed consent obtained * patients who are planned to receive a lung transplant in the near future * female patient of childbearing potential who confirm that a contraception method was used at least 14 days before screening visit and will continue to use a contraception method during the study * the patient must be able to perform the lung monitoring at home exclusion criteria: * pregnant or lactating female * known history of or active airways or anastomotic complications requiring intervention such as stenting or dilation

Keywords: hrct high resolution computed tomography scans functional respiratory imaging fri computed tomography ct bronchiolitis obliterans syndrome bos lung transplant
temozolomide in treatment of patients with primary central nervous system lymphoma

Conditions: Primary CNS Lymphoma

Summary: consolidation treatment for primary central nervous system diffuse large b cell lymphoma(pcnsl)patients remains to be defined.here we designed a tolerated treatment of hdmtx plus temozolomide,followed by consolidation with temozolomide in pcnsl patients.


Eligibility criteria:
inclusion criteria: - (1) histology confirmed to be pcnsl. (2) lymphoma invasion in brain, meninges, cerebrospinal fluid, eye organ. (3) ecog score less than 3 points (4) at least 1 of the lesions can be evaluated with a double diameter. (5) the life expectancy of more than 6 months. (6) less or equal to 75 years,or more or equal to 18 years. (7) to be able to comply with the requirements of the study and follow-up procedures. (8) to sign the consent form to participate in the study. (9) having adequate organ function, defined as follows: liver function, serum aspartate aminotransferase (ast) and serum alanine aminotransferase (alt) equal to or less than 2 times the upper limit of normal (uln). bone marrow function: absolute neutrophil count more or equal to 1500/l, platelet count more than 100000/l,hemoglobin was greater than 9 g/dl. renal function, serum creatinine or creatinine clearance rate (less than 1.5uln cockcroft-gault formula based on the improvement of more than 50ml/min). (10) women with childbearing potential must start to get the test results of serum / urine pregnancy test negative within 48 hours prior to study. postmenopausal women who have at least 12 months of menopause can be treated as non fertile. exclusion criteria: * (1) patients with a history of other malignancies within five years (except for the full treatment of cervical carcinoma in situ or basal cell carcinoma or squamous cell skin cancer). (2) had previously been treated with total cranial irradiation. (3) the upper digestive tract is lack of physical integrity, or suffering from malabsorption syndrome, or oral drug, or active gastric ulcer. (4) suffering from any unstable systemic diseases (including active infection, significant cardiovascular disease, any significant liver and kidney or metabolic disorders), metabolic disorders, physical examination results or laboratory examination results of contraindication to the use of drugs, or may affect the treatment results of interpretation or increase the risk of complications in treatment of risk (5) patients with human immunodeficiency virus (hiv) transmitted in the form of blood or other body fluids. (6) women in pregnancy and lactation. (7) women of childbearing age who do not want to use contraceptive measures during the study period and have sexual capacity of men. (8) patients who do not want to sign informed consent. (9) patients who were not willing to follow up. (10) for any drugs or excipients of allergy. exit the case: no matter what reason patients withdrew from the study of cases in time will be postponed.

Keywords: pcnsl dlbcl methotrexate temozolomide